NIH/NCI – Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (multiple RFAs)

January 17, 2019 by kjt5j@virginia.edu

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
(RFA-CA-19-023)

Revisions for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
(RFA-CA-19-024)

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)
(RFA-CA-19-025)

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
(RFA-CA-19-026)

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
(RFA-CA-19-027)

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
(RFA-CA-19-028)

Deadlines for all of these opportunities:  March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization.  Letters of intent are due 30 days prior to the deadline.

Filed Under: Funding Opportunities